Top Markets
Coin of the day
Inventiva S.A. Inventiva S.A.

Inventiva S.A.

IVA
Rang in aandelen #8990
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Aandeelprijs
$4.74
Laatst gesynchroniseerd: 2026-08-28
Marktkapitalisatie
$1.12B
Verandering (1 dag)
-5.77%
Verandering (1 jaar)
-16.96%
Land
FR
Handel Inventiva S.A. (IVA)

Categorie

Dividendrendementgeschiedenis voor Inventiva S.A. (IVA)
Het dividendrendement (TTM) van Inventiva S.A. (aandelsymbool: IVA) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Inventiva S.A. (IVA) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH